Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.
- Registration Number
- NCT01019863
- Lead Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Brief Summary
Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of patients with refractory or relapsing non-Hodgkin lymphoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Patients 18 years or above at the time of inclusion.
- Documented CD20+ NHL, refractory or relapsing after first line chemotherapy.
- No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab.
Read More
Exclusion Criteria
- Other types of non-Hodgkin lymphoma
- Pregnancy and lactation.
- Patient unable to give written informed consent.
- Contra-indication ou intolerance to any of the components of the RGDOx chemotherapy.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Oxaliplatin oxaliplatin oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma
- Primary Outcome Measures
Name Time Method Response rate to RGDOx in patients with relapsing or refractory NHL Within 3 months after chemotherapy (6-8 cycles)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
CHA Hôpital de l'Enfant-Jésus
🇨🇦Québec, Quebec, Canada
CHUS Hopital Fleurimont
🇨🇦Sherbrooke, Quebec, Canada